It was reported that helveticoside (34) represents a promising lead for developing chemopreventive agent against colorectal cancer as it exerted promising in vitro effect by increasing Bax level, inhibiting Bcl-2, and by cleaving caspase-3 and -9, leading to apoptosis (An et al., 2020). This evidence concerns the gene BAX and colorectal cancer.